Skip to main content
Equibles
BIVI logo

BIVI · Biovie Inc.

Track BIVI — free

Use BIVI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.30 +0.14 (+6.48%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These circumstances raise substantial doubt on the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-K filed Aug 13, 2026
Market Cap
$16.29M
Shares
7.54M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.16 Open$2.20 Day$2.11–2.25 52W close$0.96–2.27 Avg vol 30d9.4M Short int1.3M · 16.6% float · 1.0d Short vol49% Last earningsAug 12, 2026 DataJul 2025–Aug 2026 Filing10-K · Aug 13

Raw chart and full-history price indicators begin at the captured split on Jul 7, 2025; bars on opposite sides are not compared.

Up next

FQ1-27 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-K
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +46%
above
Price vs 50-day avg +27%
above
RSI (14) 61
neutral
MACD trend Positive
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +42%
trailing
6-month return +55%
trailing
YTD return +86%
this year
Relative strength +42%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$49.1K over 90 days · 0% sells
Short interest Rising
16.63% of float · ▲ +56.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
41 holders — mid 3-yr range
Squeeze score 70
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 116%
annualized · 1-yr
Max drawdown −58%
past year
ATR 18.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+46% Bullish
Price vs 50-day avg
+27% Bullish
RSI (14)
61 Neutral
MACD trend
Positive Bullish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+3% holders QoQ · +5 funds added
Insider flow Accumulating
Net +$49.1K over 90 days · 0% sells
Short interest Rising
16.63% of float · ▲ +56.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
41 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 92% Range high $2
vs 200-day avg +46% vs 50-day avg +27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BIVI
Biovie Inc.
this stock
$16.29M +86.2% — — 16.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.77B +2.9% +20.8% 19.7 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
41
% held
50.2%
Net QoQ
+525.5K sh
Top holder
Diametric Capital, LP
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Rising
Shares short
1.3M
Days to cover
1.0d
Change
+453.9K sh
View
Short Volume
Short vol %
49%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
323.1K
Value
$504.0K
As of
Aug 14, 2026
View
Off-Exchange
Off-exchange %
50.6%
Week of
Jul 27, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$49.1K
Buyers / Sellers
4 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-22.1M
EPS diluted
$-3.05
View
Filings
SEC Filings
Latest
10-K
Filed
Aug 13, 2026
This year
4
View
Proposed Sales
Value
$84.5K
Shares
50.0K
Filed
Dec 1, 2023
View
Exempt Offerings
Offering
$6.0M
Filed
Jul 25, 2022
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View
Investor Relations
Latest news
BioVie Announces Completion of Tr…
Published
Aug 31, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jul 7, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
BIVI +10.8% +42.1% +55.4% +42.1% +86.2%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY +10.3% +39.1% +42.0% +39.1% +73.4%
Key facts CIK 1580149 CUSIP 09074F504 13F (30d) 38 filings 36 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)